Meta-Analysis
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2022; 10(27): 9703-9713
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9703
Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
Zhong-Hui Li, Yin-Jie Ma, Zong-Hang Jia, Yue-Yan Weng, Ping Zhang, Shi-Jie Zhu, Fang Wang
Zhong-Hui Li, Yin-Jie Ma, Shi-Jie Zhu, Fang Wang, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Zong-Hang Jia, Department of Oncology, Shandong University of Traditional Chinese Medicine, Jinan 250022, Shandong Province, China
Yue-Yan Weng, Department of Acupuncture and Moxibustion, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Ping Zhang, Department of Pathology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Author contributions: Li ZH performed literature search, collected the data, statistical analysis and wrote the manuscript; Ma YJ designed the study, performed literature search, collected the data, performed statistical analysis and wrote the manuscript; Li ZH and Ma YJ have contributed equally to this work; Jia ZH performed statistical analysis, revised the manuscript and provided critical opinion; Weng YY analyzed and interpreted the data; Zhang P, Wang F, and Zhu SJ provided critical opinion and revised the manuscript; Wang F provided critical opinion, participated in literature search, and revised the manuscript; Li ZH and Ma YJ have contributed equally to this work. all authors approved the final manuscript.
Conflict-of-interest statement: The authors declare that there is no potential conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Road, Beijing 100102, China. wf074500@163.com
Received: April 3, 2022
Peer-review started: April 3, 2022
First decision: May 11, 2022
Revised: May 17, 2022
Accepted: August 15, 2022
Article in press: August 15, 2022
Published online: September 26, 2022
Processing time: 165 Days and 22 Hours
Core Tip

Core Tip: Gemcitabine plus nab-paclitaxel (GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer, and many studies will add a novel targeted agent to this regimen to improve patient survival. However, the clinical effectiveness of GA is more controversial. We conducted a meta-analysis to compare the effectiveness and safety of GA combined with a targeted agent regimen and GA regimen.